Publications by Jan Terje Andersen

65 publications found

Publications 2021

  1. Aaen KH, Anthi AK, Sandlie I, Nilsen J, Mester S, Andersen JT (2021)
    The neonatal Fc receptor in mucosal immune regulation
    Scand J Immunol, 93 (2), e13017
    DOI 10.1111/sji.13017, PubMed 33351196
  2. Høydahl LS, Frigstad T, Rasmussen IB, Øynebråten I, Schjetne KW, Andersen JT, Michaelsen TE, Lunde E, Bogen B, Sandlie I (2021)
    Antibody-mediated delivery of T-cell epitopes to antigen-presenting cells induce strong CD4 and CD8 T-cell responses
    Vaccine (in press)
    DOI 10.1016/j.vaccine.2021.02.012, PubMed 33612340

Publications 2020

  1. Azevedo C, Nilsen J, Grevys A, Nunes R, Andersen JT, Sarmento B (2020)
    Engineered albumin-functionalized nanoparticles for improved FcRn binding enhance oral delivery of insulin
    J Control Release, 327, 161-173
    DOI 10.1016/j.jconrel.2020.08.005, PubMed 32771477
  2. Bern M, Nilsen J, Ferrarese M, Sand KMK, Gjølberg TT, Lode HE, Davidson RJ, Camire RM, Bækkevold ES, Foss S, Grevys A, Dalhus B, Wilson J, Høydahl LS, Christianson GJ, Roopenian DC, Schlothauer T, Michaelsen TE, Moe MC, Lombardi S, Pinotti M, Sandlie I, Branchini A, Andersen JT (2020)
    An engineered human albumin enhances half-life and transmucosal delivery when fused to protein-based biologics
    Sci Transl Med, 12 (565)
    DOI 10.1126/scitranslmed.abb0580, PubMed 33055243
  3. Caddy SL, Vaysburd M, Wing M, Foss S, Andersen JT, O'Connell K, Mayes K, Higginson K, Iturriza-Gómara M, Desselberger U, James LC (2020)
    Intracellular neutralisation of rotavirus by VP6-specific IgG
    PLoS Pathog, 16 (8), e1008732
    DOI 10.1371/journal.ppat.1008732, PubMed 32750093
  4. Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
    Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
    Proc Natl Acad Sci U S A, 117 (40), 25018-25025
    DOI 10.1073/pnas.2010540117, PubMed 32943538
  5. Hubbard JJ, Pyzik M, Rath T, Kozicky LK, Sand KMK, Gandhi AK, Grevys A, Foss S, Menzies SC, Glickman JN, Fiebiger E, Roopenian DC, Sandlie I, Andersen JT, Sly LM, Baker K, Blumberg RS (2020)
    FcRn is a CD32a coreceptor that determines susceptibility to IgG immune complex-driven autoimmunity
    J Exp Med, 217 (10)
    DOI 10.1084/jem.20200359, PubMed 32658257
  6. Jørstad ØK, Sivertsen MS, Andersen JT, Moe MC (2020)
    Kan ampullene med covid-19-vaksine utnyttes bedre?
    Tidsskr Nor Laegeforen, 140 (2)
    DOI 10.4045/tidsskr.20.1039, PubMed 33528143
  7. Lau C, McAdam MB, Bergseth G, Grevys A, Bruun JA, Ludviksen JK, Fure H, Espevik T, Moen A, Andersen JT, Mollnes TE (2020)
    NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies
    MAbs, 12 (1), 1686319
    DOI 10.1080/19420862.2019.1686319, PubMed 31671278
  8. Nilsen J, Trabjerg E, Grevys A, Azevedo C, Brennan SO, Stensland M, Wilson J, Sand KMK, Bern M, Dalhus B, Roopenian DC, Sandlie I, Rand KD, Andersen JT (2020)
    An intact C-terminal end of albumin is required for its long half-life in humans
    Commun Biol, 3 (1), 181
    DOI 10.1038/s42003-020-0903-7, PubMed 32313072

Publications 2019

  1. Bottermann M, Foss S, Caddy SL, Clift D, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Lode HE, McAdam MB, Sandlie I, Andersen JT, James LC (2019)
    Complement C4 Prevents Viral Infection through Capsid Inactivation
    Cell Host Microbe, 25 (4), 617-629.e7
    DOI 10.1016/j.chom.2019.02.016, PubMed 30926239
  2. Foss S, Bottermann M, Jonsson A, Sandlie I, James LC, Andersen JT (2019)
    TRIM21-From Intracellular Immunity to Therapy
    Front Immunol, 10, 2049
    DOI 10.3389/fimmu.2019.02049, PubMed 31555278
  3. Labzin LI, Bottermann M, Rodriguez-Silvestre P, Foss S, Andersen JT, Vaysburd M, Clift D, James LC (2019)
    Antibody and DNA sensing pathways converge to activate the inflammasome during primary human macrophage infection
    EMBO J, 38 (21), e101365
    DOI 10.15252/embj.2018101365, PubMed 31468569
  4. Lode HE, Gjølberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, Jørstad ØK, Moe MC, Andersen JT (2019)
    A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes
    Sci Rep, 9 (1), 18021
    DOI 10.1038/s41598-019-54226-7, PubMed 31792234
  5. Maaland AF, Heyerdahl H, O'Shea A, Eiriksdottir B, Pascal V, Andersen JT, Kolstad A, Dahle J (2019)
    Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003
    Eur J Nucl Med Mol Imaging, 46 (11), 2311-2321
    DOI 10.1007/s00259-019-04417-1, PubMed 31309259
  6. Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS (2019)
    The Neonatal Fc Receptor (FcRn): A Misnomer?
    Front Immunol, 10, 1540
    DOI 10.3389/fimmu.2019.01540, PubMed 31354709
  7. Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
    Publisher Correction: Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
    Nat Nanotechnol, 14 (4), 398
    DOI 10.1038/s41565-019-0404-3, PubMed 30783200
  8. Shaw A, Hoffecker IT, Smyrlaki I, Rosa J, Grevys A, Bratlie D, Sandlie I, Michaelsen TE, Andersen JT, Högberg B (2019)
    Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies
    Nat Nanotechnol, 14 (2), 184-190
    DOI 10.1038/s41565-018-0336-3, PubMed 30643273

Publications 2018

  1. Bottermann M, Foss S, van Tienen LM, Vaysburd M, Cruickshank J, O'Connell K, Clark J, Mayes K, Higginson K, Hirst JC, McAdam MB, Slodkowicz G, Hutchinson E, Kozik P, Andersen JT, James LC (2018)
    TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination
    Proc Natl Acad Sci U S A, 115 (41), 10440-10445
    DOI 10.1073/pnas.1806314115, PubMed 30209217
  2. Grevys A, Nilsen J, Sand KMK, Daba MB, Øynebråten I, Bern M, McAdam MB, Foss S, Schlothauer T, Michaelsen TE, Christianson GJ, Roopenian DC, Blumberg RS, Sandlie I, Andersen JT (2018)
    A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
    Nat Commun, 9 (1), 621
    DOI 10.1038/s41467-018-03061-x, PubMed 29434196
  3. Nilsen J, Bern M, Sand KMK, Grevys A, Dalhus B, Sandlie I, Andersen JT (2018)
    Human and mouse albumin bind their respective neonatal Fc receptors differently
    Sci Rep, 8 (1), 14648
    DOI 10.1038/s41598-018-32817-0, PubMed 30279529
  4. Nilsen J, Sandlie I, Roopenian DC, Andersen JT (2018)
    Animal models for evaluation of albumin-based therapeutics
    Curr. Opin. Chem. Eng., 19, 68-76
  5. Sivertsen MS, Jørstad ØK, Grevys A, Foss S, Moe MC, Andersen JT (2018)
    Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
    Sci Rep, 8 (1), 2101
    DOI 10.1038/s41598-018-20525-8, PubMed 29391560
  6. Stapleton NM, Armstrong-Fisher SS, Andersen JT, van der Schoot CE, Porter C, Page KR, Falconer D, de Haas M, Williamson LM, Clark MR, Vidarsson G, Armour KL (2018)
    Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport
    Mol Immunol, 95, 1-9
    DOI 10.1016/j.molimm.2018.01.006, PubMed 29367080

Publications 2017

  1. Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2017)
    Corrigendum: Antibody-antigen kinetics constrain intracellular humoral immunity
    Sci Rep, 7, 45418
    DOI 10.1038/srep45418, PubMed 28382939
  2. Pyzik M, Rath T, Kuo TT, Win S, Baker K, Hubbard JJ, Grenha R, Gandhi A, Krämer TD, Mezo AR, Taylor ZS, McDonnell K, Nienaber V, Andersen JT, Mizoguchi A, Blumberg L, Purohit S, Jones SD, Christianson G, Lencer WI, Sandlie I, Kaplowitz N, Roopenian DC, Blumberg RS (2017)
    Hepatic FcRn regulates albumin homeostasis and susceptibility to liver injury
    Proc Natl Acad Sci U S A, 114 (14), E2862-E2871
    DOI 10.1073/pnas.1618291114, PubMed 28330995

Publications 2016

  1. Bottermann M, Lode HE, Watkinson RE, Foss S, Sandlie I, Andersen JT, James LC (2016)
    Antibody-antigen kinetics constrain intracellular humoral immunity
    Sci Rep, 6, 37457
    DOI 10.1038/srep37457, PubMed 27881870
  2. Cardoso I, Østerlund EC, Stamnaes J, Iversen R, Andersen JT, Jørgensen TJ, Sollid LM (2016)
    Dissecting the interaction between transglutaminase 2 and fibronectin
    Amino Acids, 49 (3), 489-500
    DOI 10.1007/s00726-016-2296-y, PubMed 27394141
  3. Foss S, Watkinson RE, Grevys A, McAdam MB, Bern M, Høydahl LS, Dalhus B, Michaelsen TE, Sandlie I, James LC, Andersen JT (2016)
    TRIM21 Immune Signaling Is More Sensitive to Antibody Affinity Than Its Neutralization Activity
    J Immunol, 196 (8), 3452-3459
    DOI 10.4049/jimmunol.1502601, PubMed 26962230

Publications 2015

  1. Bern M, Sand KM, Nilsen J, Sandlie I, Andersen JT (2015)
    The role of albumin receptors in regulation of albumin homeostasis: Implications for drug delivery
    J Control Release, 211, 144-62
    DOI 10.1016/j.jconrel.2015.06.006, PubMed 26055641
  2. Cardoso I, Stamnaes J, Andersen JT, Melino G, Iversen R, Sollid LM (2015)
    Transglutaminase 2 interactions with extracellular matrix proteins as probed with celiac disease autoantibodies
    FEBS J, 282 (11), 2063-75
    DOI 10.1111/febs.13276, PubMed 25808416
  3. Chen X, Hnida K, Graewert MA, Andersen JT, Iversen R, Tuukkanen A, Svergun D, Sollid LM (2015)
    Structural Basis for Antigen Recognition by Transglutaminase 2-specific Autoantibodies in Celiac Disease
    J Biol Chem, 290 (35), 21365-75
    DOI 10.1074/jbc.M115.669895, PubMed 26160175
  4. Czajkowsky DM, Andersen JT, Fuchs A, Wilson TJ, Mekhaiel D, Colonna M, He J, Shao Z, Mitchell DA, Wu G, Dell A, Haslam S, Lloyd KA, Moore SC, Sandlie I, Blundell PA, Pleass RJ (2015)
    Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications
    Sci Rep, 5, 9526
    DOI 10.1038/srep09526, PubMed 25912958
  5. Foss S, Grevys A, Sand KMK, Bern M, Blundell P, Michaelsen TE, Pleass RJ, Sandlie I, Andersen JT (2015)
    Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
    J Control Release, 223, 42-52
    DOI 10.1016/j.jconrel.2015.12.033, PubMed 26718855
  6. Foss S, Watkinson R, Sandlie I, James LC, Andersen JT (2015)
    TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity
    Immunol Rev, 268 (1), 328-39
    DOI 10.1111/imr.12363, PubMed 26497531
  7. Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT (2015)
    Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
    J Immunol, 194 (11), 5497-508
    DOI 10.4049/jimmunol.1401218, PubMed 25904551
  8. Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT (2015)
    Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
    Front Immunol, 5, 682
    DOI 10.3389/fimmu.2014.00682, PubMed 25674083

Publications 2014

  1. Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, Allan E, Evans L, Bjørås M, Kjærulff S, Sleep D, Sandlie I, Cameron J (2014)
    Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding
    J Biol Chem, 289 (19), 13492-502
    DOI 10.1074/jbc.M114.549832, PubMed 24652290
  2. Einarsdottir HK, Stapleton NM, Scherjon S, Andersen JT, Rispens T, van der Schoot CE, Vidarsson G (2014)
    On the perplexingly low rate of transport of IgG2 across the human placenta
    PLoS One, 9 (9), e108319
    DOI 10.1371/journal.pone.0108319, PubMed 25251461
  3. Hallstensen RF, Bergseth G, Foss S, Jæger S, Gedde-Dahl T, Holt J, Christiansen D, Lau C, Brekke OL, Armstrong E, Stefanovic V, Andersen JT, Sandlie I, Mollnes TE (2014)
    Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn
    Immunobiology, 220 (4), 452-9
    DOI 10.1016/j.imbio.2014.11.003, PubMed 25468724
  4. Rahman MA, Kristiansen PE, Veiseth SV, Andersen JT, Yap KL, Zhou MM, Sandlie I, Thorstensen T, Aalen RB (2014)
    The arabidopsis histone methyltransferase SUVR4 binds ubiquitin via a domain with a four-helix bundle structure
    Biochemistry, 53 (13), 2091-100
    DOI 10.1021/bi401436h, PubMed 24625295
  5. Sand KM, Bern M, Nilsen J, Dalhus B, Gunnarsen KS, Cameron J, Grevys A, Bunting K, Sandlie I, Andersen JT (2014)
    Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn)
    J Biol Chem, 289 (50), 34583-94
    DOI 10.1074/jbc.M114.587675, PubMed 25344603
  6. Sand KM, Dalhus B, Christianson GJ, Bern M, Foss S, Cameron J, Sleep D, Bjørås M, Roopenian DC, Sandlie I, Andersen JT (2014)
    Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies
    J Biol Chem, 289 (24), 17228-39
    DOI 10.1074/jbc.M113.522565, PubMed 24764301

Publications 2013

  1. Andersen JT, Cameron J, Plumridge A, Evans L, Sleep D, Sandlie I (2013)
    Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics
    J Biol Chem, 288 (33), 24277-85
    DOI 10.1074/jbc.M113.463000, PubMed 23818524
  2. Andersen JT, Gonzalez-Pajuelo M, Foss S, Landsverk OJ, Pinto D, Szyroki A, de Haard HJ, Saunders M, Vanlandschoot P, Sandlie I (2013)
    Selection of nanobodies that target human neonatal Fc receptor
    Sci Rep, 3, 1118
    DOI 10.1038/srep01118, PubMed 23346375
  3. Jacobsen JT, Sundvold-Gjerstad V, Skjeldal FM, Andersen JT, Abrahamsen G, Bakke O, Spurkland A, Bogen B (2013)
    B-cell tolerance to the B-cell receptor variable regions
    Eur J Immunol, 43 (10), 2577-87
    DOI 10.1002/eji.201243203, PubMed 23839948
  4. Lau C, Gunnarsen KS, Høydahl LS, Andersen JT, Berntzen G, Pharo A, Lindstad JK, Ludviksen JK, Brekke OL, Barratt-Due A, Nielsen EW, Stokes CR, Espevik T, Sandlie I, Mollnes TE (2013)
    Chimeric anti-CD14 IGG2/4 Hybrid antibodies for therapeutic intervention in pig and human models of inflammation
    J Immunol, 191 (9), 4769-77
    DOI 10.4049/jimmunol.1301653, PubMed 24062486
  5. Mathiesen L, Nielsen LK, Andersen JT, Grevys A, Sandlie I, Michaelsen TE, Hedegaard M, Knudsen LE, Dziegiel MH (2013)
    Maternofetal transplacental transport of recombinant IgG antibodies lacking effector functions
    Blood, 122 (7), 1174-81
    DOI 10.1182/blood-2012-12-473843, PubMed 23843496

Publications 2012

  1. Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjørås M, Sleep D, Sandlie I (2012)
    Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
    Nat Commun, 3, 610
    DOI 10.1038/ncomms1607, PubMed 22215085
  2. Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I (2012)
    Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life
    J Biol Chem, 287 (27), 22927-37
    DOI 10.1074/jbc.M112.355131, PubMed 22570488
  3. Jung ST, Kelton W, Kang TH, Ng DT, Andersen JT, Sandlie I, Sarkar CA, Georgiou G (2012)
    Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity
    ACS Chem Biol, 8 (2), 368-75
    DOI 10.1021/cb300455f, PubMed 23030766
  4. Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, Orcutt KD, Wittrup KD, Shively JE, Raubitschek A, Colcher D (2012)
    A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance
    Protein Eng Des Sel, 26 (3), 187-93
    DOI 10.1093/protein/gzs096, PubMed 23175797

Publications 2011

  1. Baker K, Qiao SW, Kuo TT, Aveson VG, Platzer B, Andersen JT, Sandlie I, Chen Z, de Haar C, Lencer WI, Fiebiger E, Blumberg RS (2011)
    Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
    Proc Natl Acad Sci U S A, 108 (24), 9927-32
    DOI 10.1073/pnas.1019037108, PubMed 21628593
  2. Mekhaiel DN, Czajkowsky DM, Andersen JT, Shi J, El-Faham M, Doenhoff M, McIntosh RS, Sandlie I, He J, Hu J, Shao Z, Pleass RJ (2011)
    Polymeric human Fc-fusion proteins with modified effector functions
    Sci Rep, 1, 124
    DOI 10.1038/srep00124, PubMed 22355641
  3. Stapleton NM, Andersen JT, Stemerding AM, Bjarnarson SP, Verheul RC, Gerritsen J, Zhao Y, Kleijer M, Sandlie I, de Haas M, Jonsdottir I, van der Schoot CE, Vidarsson G (2011)
    Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential
    Nat Commun, 2, 599
    DOI 10.1038/ncomms1608, PubMed 22186895

Publications 2010

  1. Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsén L, Ekblad C (2010)
    Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
    J Biol Chem, 286 (7), 5234-41
    DOI 10.1074/jbc.M110.164848, PubMed 21138843

Publications 2009

  1. Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I (2009)
    Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding
    J Biol Chem, 285 (7), 4826-36
    DOI 10.1074/jbc.M109.081828, PubMed 20018855
  2. Andersen JT, Daba MB, Sandlie I (2009)
    FcRn binding properties of an abnormal truncated analbuminemic albumin variant
    Clin Biochem, 43 (4-5), 367-72
    DOI 10.1016/j.clinbiochem.2009.12.001, PubMed 20006594
  3. Andersen JT, Sandlie I (2009)
    The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics
    Drug Metab Pharmacokinet, 24 (4), 318-32
    DOI 10.2133/dmpk.24.318, PubMed 19745559

Publications 2008

  1. Berntzen G, Andersen JT, Ustgård K, Michaelsen TE, Mousavi SA, Qian JD, Kristiansen PE, Lauvrak V, Sandlie I (2008)
    Identification of a high affinity FcgammaRIIA-binding peptide that distinguishes FcgammaRIIA from FcgammaRIIB and exploits FcgammaRIIA-mediated phagocytosis and degradation
    J Biol Chem, 284 (2), 1126-35
    DOI 10.1074/jbc.M803584200, PubMed 18957413
  2. Qiao SW, Kobayashi K, Johansen FE, Sollid LM, Andersen JT, Milford E, Roopenian DC, Lencer WI, Blumberg RS (2008)
    Dependence of antibody-mediated presentation of antigen on FcRn
    Proc Natl Acad Sci U S A, 105 (27), 9337-42
    DOI 10.1073/pnas.0801717105, PubMed 18599440

Publications 2007

  1. Andersen JT, Justesen S, Berntzen G, Michaelsen TE, Lauvrak V, Fleckenstein B, Buus S, Sandlie I (2007)
    A strategy for bacterial production of a soluble functional human neonatal Fc receptor
    J Immunol Methods, 331 (1-2), 39-49
    DOI 10.1016/j.jim.2007.11.003, PubMed 18155020
  2. Andersen JT, Sandlie I (2007)
    A receptor-mediated mechanism to support clinical observation of altered albumin variants
    Clin Chem, 53 (12), 2216
    DOI 10.1373/clinchem.2007.097071, PubMed 18267931

Publications 2006

  1. Andersen JT, Dee Qian J, Sandlie I (2006)
    The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin
    Eur J Immunol, 36 (11), 3044-51
    DOI 10.1002/eji.200636556, PubMed 17048273

Publications 2005

  1. Berntzen G, Lunde E, Flobakk M, Andersen JT, Lauvrak V, Sandlie I (2005)
    Prolonged and increased expression of soluble Fc receptors, IgG and a TCR-Ig fusion protein by transiently transfected adherent 293E cells
    J Immunol Methods, 298 (1-2), 93-104
    DOI 10.1016/j.jim.2005.01.002, PubMed 15847800

 
Page visits: 1775